What The Study Did: This analysis of more than 31,000 compassionate use requests for unlicensed products for patients with serious medical conditions examined the disparities in access observed across countries and the key factors.
Authors: Paul Aliu, Pharm.D., M.R.Pharm.S., G.Dip. (Law), M.B.A., of Novartis Pharma AG in Basel, Switzerland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2022.0475)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2022.0475?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041522
About JAMA Health Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.
JAMA Health Forum